---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-082314"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T13:33:23.991683+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion reports 89% response rate and 1% median HbA1c reduction at 4 weeks for BMF-219 in T2DM Phase II

## Summary
- Cohort 3 (100 mg BMF-219 without food, n=9) showed 89% response rate, median HbA1c reduction of -1.0% at day 28.
- 56% of Cohort 3 patients achieved >=1.0% HbA1c reduction; placebo (n=4) had median reduction of -0.1% to -0.15%.
- BMF-219 was well-tolerated; no discontinuations, serious AEs, or severe AEs across healthy volunteers and T2DM cohorts.
- Company plans to explore additional dosing periods >4 weeks and potential utility in type 1 diabetes.
- Dose escalation continues; negative food effect observed (3-fold exposure difference between fed and fasted cohorts).

## SEC filing metadata
- accession: 0001193125-23-082314
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312523082314/0001193125-23-082314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312523082314/d311150d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-082314
- JSON: https://secwatch.observer/filing/0001193125-23-082314.json
- Plain text: https://secwatch.observer/filing/0001193125-23-082314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.